Spectral AI (MDAI) Q3 2026 earnings review
Spectral AI starts building scanners, but cuts its revenue plan
Spectral AI, a developer of medical scanners for burn wounds, cut its annual revenue plan as government contract work slowed. Third-quarter revenue dropped 25% to $2.9 million because a military handheld contract ended and its main federal agency partner shifted reimbursements into later periods. Chief executive Vincent Capone lowered the full-year revenue forecast to $13.0 million, which by our math leaves $2.6 million for the fourth quarter.
| Research and development revenue | $2.9M -25% from a year ago |
|---|---|
| Gross margin | 27.2% 42.7% a year ago |
| Cash and cash equivalents | $11.2M $14.0M last quarter |
| Full-year 2026 revenue outlook | Cut $5.5M to ~$13.0M (-34% from 2025) |
⚖️ Verdict: 🔴 Bearish
The story got worse because the second-half revenue rebound management counted on did not happen, leaving less cash for the commercial rollout. Gross margin shrank to 27% as the company paid its share of government development costs, while cash fell to $11.2 million and short-term debt rose to $8.0 million. On the other side, the firm started building its first 30 DeepView scanners and remains on track for initial US deliveries by year-end.
The question now is how much new capital Spectral AI must raise before hospital placements begin paying the bills. Either the first 30 government-backed systems convert quickly into paid contracts, or slow hospital adoption and a Medicare reimbursement decision due in August 2027 force the company to sell more shares. The fourth-quarter placement count and the upcoming quarterly filing's cash flow statement will tell.
🐂 Bull Case
Manufacturing Starts for First 30 BARDA Systems
Spectral AI makes the DeepView AI System, a medical scanner that helps doctors see if a burn wound will heal without surgery. The Biomedical Advanced Research and Development Authority (BARDA), a US government agency, is paying to place the first 30 machines in US burn centers through June 2027.
"We have begun manufacturing the first 30 DeepView AI Systems for BARDA-supported deployment at U.S. burn centers and remain on track for initial deliveries by year-end," chief executive Vincent Capone said. Getting those first machines into hospitals this year is the prerequisite for collecting software fees in 2027.
What to watch: the exact number of systems placed by December 31, 2026, which the medical diagnostics company will report in its fourth-quarter release. Any count above zero will confirm that the US hospital rollout has started on schedule.
UK Burn Study Enrolls First Ten Patients
US regulators cleared the DeepView scanner in May 2026, but the approval did not cover burns on the head, hands, and feet. Spectral AI is running a clinical study in the United Kingdom so doctors can use the scanner on those harder-to-treat body parts.
During the third quarter, the Dallas-based company opened all four UK burn centers for the trial and enrolled its first ten patients. That trial work lifted research and development spending by 30% from a year ago, to $2.0 million, or 29.3 percentage points of revenue by our math.
What to watch: UK regulatory clearance for the updated DeepView system, which management previously targeted by the end of 2026. Receiving that clearance will let the firm begin placing machines in the United Kingdom and Australia.
🐻 Bear Case
BARDA Cost-Sharing and Delays Cut 2026 Revenue
Spectral AI still relies on one customer for almost all of its income. BARDA provided 94.5% of third-quarter sales by our math, because a smaller military contract with the Medical Technology Enterprise Consortium (MTEC) for a handheld scanner finished with no follow-on awards this year.
Because the current BARDA phase requires the company to pay part of the development bill, both revenue and profit margins dropped. Spectral AI cut its 2026 revenue plan by $5.5 million, citing the ended military work and "the timing of research and development activities reimbursed under the BARDA contract, which moves revenue into future periods within the existing contract term".
- Third-quarter BARDA revenue: $2.7 million, down 21% from $3.4 million a year ago
- Other government revenue: $0.1 million, down from $0.4 million as MTEC work ended
- Gross margin: 27.2%, down 15.5 percentage points because cost of revenue rose to 72.8% of sales
- Implied fourth-quarter revenue: $2.6 million by our math, down 32% from a year ago
What to watch: fourth-quarter BARDA revenue and the start of the 12-center US clinical outcome study. If study work does not pick up in early 2027, low government reimbursements will force the business to burn through its cash reserves faster.
Cash Burn and Rising Short-Term Debt
Funding its own share of BARDA development and preparing for product sales is draining Spectral AI's bank account, while debt payments are drawing closer. Finance chief David McGuire noted the $11.2 million cash balance and said management is "assessing opportunities to strengthen our balance sheet as we move from development to commercialization".
- Cash balance: $11.2 million, down $2.8 million from $14.0 million in the second quarter
- Short-term notes payable: $8.0 million, up from $3.9 million last quarter as debt moves closer to maturity
- Total notes payable: $15.5 million, leaving $4.2 million in net debt by our math
- Share count: 32.2 million weighted-average shares, up 22.3% from a year ago, plus $11.0 million in warrant liabilities
The press release did not include a cash flow statement, so nine-month operating cash burn is not readable until the quarterly filing arrives. At last quarter's $2.8 million cash drop, existing funds cover about four quarters before counting debt repayments.
What to watch: the nine-month operating cash flow figure and debt repayment schedule in the Form 10-Q filing due by November 16. A high cash burn rate will point to additional share sales that dilute current owners.
Commercial Launch Nears Without Pricing or Reimbursement
Capone said the group is "looking beyond early deployments to build the capabilities that will support broader adoption and establish a repeatable clinical model". To support that push, the company showcased DeepView at medical conferences and raised selling and marketing spending by 12.8% from a year ago, to $0.4 million (up 4.8 percentage points of revenue).
However, the pieces needed to earn money from non-BARDA hospitals are still missing or months away. Spectral AI applied to the Centers for Medicare & Medicaid Services (CMS), the federal health agency, for a New Technology Add-On Payment (NTAP) to "provide hospitals with additional Medicare reimbursement for use of the DeepView AI System", but a decision is not due until August 2027. Management still has not disclosed what it will charge for a scanner, and the 2026 revenue plan includes zero commercial sales.
What to watch: whether the fourth-quarter report discloses per-system pricing or lease terms alongside the first BARDA deliveries. Without disclosed pricing or Medicare coverage until late 2027, hospital adoption outside the government contract will stay slow.
👓 Other Themes
Lower Legal Bills Cut Overhead Spending
While clinical trial and marketing budgets grew, Spectral AI trimmed its administrative overhead. General and administrative expenses—the day-to-day costs of running the business, such as executive pay and outside advisers—dropped 23.6% from a year ago, from $3.1 million to $2.3 million, on lower legal and professional fees. Because revenue fell slightly faster, administrative costs still edged up by 1.2 percentage points of sales to 82.0% by our math, while total operating expenses declined 4.4% to $4.7 million.
💲 Other KPIs
Operating loss narrowed from $4.32 million last quarter as legal costs fell, though it remained wider than the $3.34 million loss a year ago. Loss before interest, taxes, depreciation, and one-offs (Adjusted EBITDA) was $3.66 million. Reported net loss of $3.66 million benefited from an $825 thousand non-cash accounting gain on warrant liabilities.
Deferred revenue—cash received from customers for work not yet performed—climbed to $570 thousand at the end of September, up from $21 thousand in the second quarter and $154 thousand at the end of 2025. That advance funding will turn into reported revenue as Spectral AI completes the contracted development tasks.
Inventory rose 14.4% from $815 thousand in the second quarter and is up 11.2% from $838 thousand at the end of 2025. The build-up in parts and finished hardware matches management's statement that the company has started building the first 30 DeepView scanners for year-end delivery.
🔮 Guidance
Cut. Management lowered its full-year revenue forecast by $5.5 million, or 30%, meaning annual sales will drop about 34% from 2025. By our math, the new target leaves $2.6 million for the fourth quarter, down from $2.9 million in the third quarter and 32% below a year ago. The company cited the finished military handheld contract and BARDA development work shifting into later years, noting the plan still excludes any DeepView scanner sales.
❓ Key Questions
What was nine-month operating cash burn?
The earnings release omitted the cash flow statement ahead of the Form 10-Q filing due by November 16. With cash down $2.8 million in the quarter to $11.2 million, investors need to see the exact operating burn rate.
How will Spectral AI strengthen its balance sheet?
Finance chief David McGuire said the company is assessing options to bolster its finances, and short-term debt jumped from $3.9 million to $8.0 million. Shareholders need to know if management plans to sell more stock before loan payments begin in April 2027.
When will the delayed BARDA revenue be recognized?
Cutting the 2026 revenue plan by $5.5 million removed the fourth-quarter BARDA ramp management had pointed to three months ago. Investors need the updated quarterly schedule for the remaining BARDA contract funds across 2027 and 2028.
What is the price of a DeepView system?
Spectral AI is manufacturing its first 30 systems for delivery starting this year, and completed a pricing study earlier in 2026, but still has not told investors the purchase price, lease rate, or annual software fee per hospital.